✦ LIBER ✦

1009 Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas

✍ Scribed by O'Connor, O.A.; Wright, J.; Moskowitz, C.; Straus, D.; MacGregor-Cortelli, B.; Muzzy, J.; Choi, P.; Schenkein, D.; Zelenetz, A.D.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Marked Clinical Activity of the Proteaso

✍ O'Connor, Owen A. 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 389 KB

Phase II study of the proteasome inhibit

✍ Li, Tianhong; Ho, Liawaty; Piperdi, Bilal; Elrafei, Tarek; Camacho, Fernando J.; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 240 KB

A multicentre phase II clinical experien

✍ Owen A. O’Connor; Carol Portlock; Craig Moskowitz; David Straus; Paul Hamlin; Mi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

Phase II 2-arm trial of the proteasome i

✍ Jill Gilbert; Ju Whei Lee; Athanassios Argiris; Missak Haigentz Jr.; Lawrence Er 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 776 KB